Ispol'zovanie kliniko-laboratornykh prediktorov v prognozirovanii antisekretornogo i antiproliferativnogo deystviya analogov somatostatina pri lechenii akromegalii: obzor poslednikh issledovaniy


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

This review is dedicated to the current problems of pharmacotherapy of acromegaly. The mechanisms of antisecretory and antiproliferative action of somatostatin analogues, as well as the use of clinical and laboratory predictors for prognostication of effectiveness of a primary or secondary pharmacotherapy are discussed. The results of a meta-analysis and some clinical studies on this subject are presented.

全文:

受限制的访问

参考

  1. Dekkers O.M., Biermasz N.R., Pereira A.M. Mortality in acromegaly: a metaanalysis. J. Clin. Endocrinol. Metab. 2008;93:61-7.
  2. McCabe J., Ayuk J., Sherlock M. Treatment Factors that Influence Mortality in Acromegaly. Neuroendocrinology 2015 Jan 30.
  3. Анциферов М.Б., Пронин В.С., Алексеева Т.М. Московский регистр больных гипофизарным гигантизмом и акромегалией (современное состояние и перспективы развития). М., 2014.
  4. Kontogeorgos G. Predictive markers of pituitary adenoma behavior. Neuroendocrinology. 2006;83(3-4):179-188.
  5. Mete O, Ezzat S., Asa S.L. Biomarkers of aggressive pituitary adenomas. J. Mol. Endocrinol. 2012;49(2):R69-R78.
  6. Chatzellis E, Alexandraki K.I, Androulakis I.I., Katlas G. Aggressive Pituitary Tumors. Neuroendocrinology, 2015 Jan 5.
  7. Fougner S.L., Borota O.C., Berg J.P., et al. The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clin. Endocrinol. (Oxf) 2008;68(3):458-65.
  8. Casarini A.P., Jallad R.S., Pinto E.M, Soares I.C. Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment Neuroendocrinology, 2015.
  9. Diri H. Ozaslan E., Kurtsoy A., Tucer B., Simsek Y., Ozturk F., Durak A.C., Bayram F. Prognostic Factors Obtained from Long-Term Follow-up of Pituitary Adenomas and Other Sellar Tumors. Turk Neurosurg 2014;24(5):679-87.
  10. Larkin S., Reddy R., Karavitaki N., Cudlip S., Wass J., Ansorge O. Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas. Eur. J. Endocrinol. 2013;168(4):491-99.
  11. Bzana J., Yedinak C.G, Guitekin S.H., et al. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. Pituitary. 2013;16(4):490-98.
  12. Puig-Domingo M., Resmini E., Gomez-Anson B., Nicolau J., Mora M., Palomera E., Marti C., Halperin I., Webb S.M. Magnetic resonance imaging as a predictor of response to somatostatin analog in acromegaly after surgical failure. J. Clin. Endocrinol. Metab. 2010; 95(11):4973-78.
  13. Melmed S., Molitch M., Grossman A.B., Kleinberg D., Clemmons D., Chanson P., Laws E., Schlechte J., Vance M.L., Ho K., Giustina A.; Acromegaly Consensus Group. Guidelines for Acromegaly Management: an update. Clin. Endocrinol. Metab. 2009;94(5):1509-17.
  14. Katznelson L., Atkinson J.L.D., Cook D.M., Ezzat S.Z., Hamrahian A.H., Miller K.K.; American Association of Clinical Endocrinologists American Association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly. Endocrine practice. 2011;17(4):1-44.
  15. Lenzi J., Lapadula G., Damico T. Evaluation of trans-sphenoidal surgery in pituitary GH-secreting micro- and macroadenomas: a comparison between microsurgical and endoscopic approach. J. Neurosurg Sci. 2015;59(1):11-8.
  16. Barkan A.L. Radiotherapy in acromegaly: the argument against. Clin. Endocrinol. 2003;58:132-35.
  17. Giustina A., Chanson P., Kleinberg D., Bron-stein M.D., Clemmons D.R., Klibanski A., van der LelyA.J., Strasburger C.J., Lamberts S.W, Ho K.K., Casanueva F.F., Melmed S.; Acromegaly Consensus Group. Expert consensus document: A consensus on the medical treatment of acromegaly. Nat. Rev. Endocrinol. 2014; 10:243-48.
  18. Zatelli M.C., Ambrosio M.R., Bondanelli M., Uberti E.C. Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds. Eur. J. Endocrinol. 2007;156(Suppl. 1):29-35.
  19. Bevan J.S. The anti-tumoral effects of somatostatin analog therapy in acromegaly. J. Clin. Edocrinol. Metab. 2005;90:1856-63.
  20. Colao A., Pivonello R., Auriemma R.S., Briganti F., Galdiero M., Tortora F., Caranci F., Cirillo S., Lombardi G. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J. Clin. Endocrinol. Metab. 2006; 91(6):2112-18.
  21. Cuevas-Ramos D., Freseriu M. Somatostatin receptor ligands and resistance to treatment in pituitary adenomas. J. Mol. Endocrinol. 2014;52(3):223-40.
  22. Alimonamadi M., Ownagh V., Mahouzi L., Ostovar A., Abbassioun K., Amirjmshidi A. The impact of immunohistochemical markers of Ki-67 and p53 on the long-term outcome of growth hormone-secreting pituitary adenomas: A cohort study, Asian J. Neurosurgery. 2014;9(3):130-36.
  23. Taboada G.F.,Lugue R.M.,NetoL.V.,MachadoEde O., Sbaffi B.C., Domingues R.C., Marcondes J.B., Chimelli L.M., Fontes R., Niemeyer P., de Carvalho D.P., Kineman R.D., Gadelha M.R. Quantitative analysis os somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur. J. Endocrinol. 2008;158:295-303.
  24. Neto L.V., Machado Ede O., Luque R.M., et al. Expression analysis of dopamine receptor subtypes in normal human pituitaries, non function pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. J. Clin. Endocrinol. Metab. 2009;94:1931-37.
  25. Пронин В.С., Потешкин Ю.Е., Гитель Е.П. Современная стратегия диагностики и лечения соматотропином. М., 2013. 191 с.
  26. Halah F.P., Elias L.L., Martinelli C.E., Castro M., Moreira A.C. Usefulness of subcutaneous or lon-gacting octreotide as a predictive test and in the treatment of acromegaly. Arg. Bras. Endocrinol. Metab. 2004;48:245-52.
  27. Halperin I., Nicolau J.,Casamitjana R., Sesmilo G., Serra-Prat M, Palomera E., Puig-Domingo M. A short acute octreotide suppression test for response prediction of long-term treatment with somatostatin analogues in acromegalic patients Horm. Metab. Res. 2008;40:422-26.
  28. Bandgar T.R., Sarathi V., Shivane V., Bansode N., Menon P.S., Shah N.S. The value of an acute octreotide suppression test in predicting response to long-term somatostatin analogue therapy in patients with acromegaly. J. Postgrad. Med. 2010;56:7-11.
  29. Domingo M.P. Treatment of acromegaly in the era of personalized and predictive medicine. Clin. Endocrinol. (Oxf). 2015.
  30. Carrasco C.A. Gadella M., Manavela M., Bruno O.D. Aggressive tumors and difficult choices in acromegaly. Pituitary. 2014;17(Suppl. 1):24-9.
  31. Baldys- Waligorskа A., Krzentowska-Korek A., Golkowski F., Sokolowski G., Hubalewska-Dydejczyk A. The predictive value of the IGF-1 level in acromegaly patients treated by surgery and a somatostatin analogs. Endocrynologia Polska/Polish Journal of Endocrinology. 2011;62(5):401-08.
  32. Giustina A., Bronstein M.D., Casanueva F.F., et al. Current management practices for acromegaly: an international survey. Pituitary. 2010;14(2):125-33.
  33. John S., et al. Tumour and hormonal response with lanreotide Autogel 120 mg. 16-th European Congress of Endocrinology, Wroclaw, Poland, May 3-7, 2014. Р. 911.
  34. Chalabi M., Duluc C., Caron P., Vezzosi D., Guillermet-Guibert J., Pyronnet S., Bousquet C. Somatostatin analogs: does pharmacology impact antitumor efficacy? Trends Endocrinol. Metab. 2014;25(3):115-27.
  35. Caron P.J., Bevan J.S., Petersenn S., Flanagan D., Tabarin A., Prevost G., Maisonobe P., Clermont A. PRIMARYS Investigators.Tumor Shrinkage with Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial. J. Clin. Endocrinol. Metab. 2013.
  36. Caron P. Relationship between early and longterm tumour volume reduction with primary lanreotide Autogel therapy in treatment naive acromegalie patients: post-hoc analyses of the PRYMARYS study, 16-th European Congress of Endocrinology, Wroclaw, Poland, May 3-7. 2014. Р. 910.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##